Literature DB >> 33367693

Cardiac recovery following left ventricular assist device therapy: experience of complete device explantation including ventricular patch plasty.

Takayuki Gyoten1, Sebastian V Rojas1, Henrik Fox1, Masatoshi Hata1, Marcus-André Deutsch1, René Schramm1, Jan F Gummert1, Michiel Morshuis1.   

Abstract

OBJECTIVES: Myocardial recovery is a rare phenomenon in left ventricular assist device (LVAD) therapy. Surgical LVAD removal is associated with the risk of cardiac failure, and the individual evaluation of sufficient myocardial recovery is crucial. Thus, complete device explantation is not consistently performed to minimize perioperative risk. However, the remaining ventricular assist device components bear significant risks of infection or thrombosis. Therefore, we developed this study to evaluate a complete LVAD explantation protocol.
METHODS: All patients in our institution who had an LVAD explanted were enrolled in the study. Explant surgery involved removal of the driveline, pump housing, sewing ring and outflow graft. The ventricular wall was reconstructed by double patch plasty. Our analysis focused on surgical and postoperative outcome parameters, including all-cause mortality and major adverse cardiac and cerebrovascular events.
RESULTS: A total of 12 patients (HVAD, n = 5; HeartMate II, n = 3; HeartMate 3, n = 4) had myocardial recovery and qualified for our LVAD explantation study protocol [median age: 40 years, interquartile range (IQR) 33-52 years; 50% men]. Primary heart failure aetiology: myocarditis (n = 5), dilated cardiomyopathy (n = 4), toxic cardiomyopathy (n = 2) and valvular heart failure (n = 1). The median average duration on LVAD was 10 months (25-75%: IQR 8.5-30 months). The median left ventricular ejection fraction was 15% (IQR 13-18%) at LVAD implantation and 50% (IQR 45-50%) before LVAD explantation (P = 0.0025).The 30-day survival was 100%. The 1-year survival was 91.7%. All patients were discharged after a median 13 days (IQR 10-18 days) postoperatively. No patient had major adverse cardiac and cerebrovascular events. The New York Heart Association functional class remained consistent during the follow-up period (median New York Heart Association functional class: II, IQR II-II class) including preservation of ventricular function.
CONCLUSIONS: Complete LVAD explantation with ventricular patch plasty is feasible and has consistent long-term results.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  HVAD; Heart failure; HeartMate; Left ventricular assist device explantation; Weaning protocol

Year:  2021        PMID: 33367693     DOI: 10.1093/ejcts/ezaa461

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events.

Authors:  Eleanor F Gerhard; Lu Wang; Ramesh Singh; Stephan Schueler; Leonard D Genovese; Andrew Woods; Daniel Tang; Nicola Robinson Smith; Mitchell A Psotka; Sian Tovey; Shashank S Desai; Djordje G Jakovljevic; Guy A MacGowan; Palak Shah
Journal:  J Heart Lung Transplant       Date:  2021-08-11       Impact factor: 10.247

2.  Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy.

Authors:  Takayuki Gyoten; Eisuke Amiya; Osamu Kinoshita; Masaki Tsuji; Mitsutoshi Kimura; Masaru Hatano; Minoru Ono
Journal:  ESC Heart Fail       Date:  2022-05-10

3.  Results from a multicentre evaluation of plug use for left ventricular assist device explantation.

Authors:  Evgenij V Potapov; Nikolaos Politis; Matthias Karck; Michael Weyand; René Tandler; Thomas Walther; Fabian Emrich; Hermann Reichenspurrner; Alexander Bernhardt; Markus J Barten; Peter Svenarud; Jan Gummert; Davorin Sef; Torsten Doenst; Dmytro Tsyganenko; Antonio Loforte; Felix Schoenrath; Volkmar Falk
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.